Other Information
−Removed: (c) During the three months ended September 30, 2024, the following director and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
−Removed: Clancy , a member of our Board of Directors , adopted a trading plan on August 20, 2024 providing for the sale of up to an aggregate of 45,000 shares of our common stock until August 20, 2025 .
−Removed: Steven Stein , our Executive Vice President and Chief Medical Officer , adopted a trading plan on August 29, 2024 providing for the sale of up to an aggregate of 29,745 shares of our common stock until August 29, 2025 .
−Removed: Vijay Iyengar , our Executive Vice President, Global Medical Affairs, Product, and Partnership Strategy , adopted a trading plan on August 29, 2024 providing for the sale of up to an aggregate of 77,316 shares of our common stock until August 29, 2025 .
−Removed: Thomas Tray , our Vice President, Chief Accounting Officer , adopted a trading plan on September 13, 2024 providing for the sale of up to an aggregate of 1,300 shares of our common stock until September 15, 2025 .
−Removed: During the three months ended September 30, 2024, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
+Added: (c) During the three months ended March 31, 2025, the following officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted a prearranged trading plan relating to our common stock and intended to satisfy the affirmative defense of Rule 10b5–1(c) under the Securities Exchange Act of 1934:
+Added: Thomas Tray , our Vice President, Chief Accounting Officer , adopted a trading plan on February 28, 2025 providing for the sale of up to an aggregate of 1,614 shares of our common stock until February 28, 2026 .
+Added: During the three months ended March 31, 2025, no director or officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934) of our Company adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities, whether or not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), other than as set forth above.
Number Description of Document
−Removed: 10.1#* Form of U.S.
−Removed: Stock Option Agreement for Executive Officers under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan.
−Removed: 10.2#* Form of U.S.
−Removed: Restricted Stock Unit Award Agreement under the Incyte Corporation Amended and Restated 2010 Stock Incentive Plan.
−Removed: 10.3#* Form of U.S.
−Removed: Nonstatutory Stock Option Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan.
−Removed: 10.4#* Form of U.S.
−Removed: Restricted Stock Unit Award Agreement for Executive Officers under the Incyte Corporation 2024 Inducement Stock Incentive Plan.
+Added: 10.1* Extension, dated as of March 12, 2025, to the Amendment, dated as of March 20, 2020, to the Collaboration and License Agreement entered into as of November 24, 2009, by and between the Company and Novartis International Pharmaceutical Ltd.
31.1* Rule 13a-14(a) Certification of Chief Executive Officer .
19 unchanged sentences
INCYTE CORPORATION
−Removed: October 29, 2024
+Added: April 29, 2025
/s/ HERVÉ HOPPENOT
2 unchanged sentences
(Principal Executive Officer)
−Removed: October 29, 2024
+Added: April 29, 2025
/s/ CHRISTIANA STAMOULIS
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.